| アブストラクト | INTRODUCTION: An increased risk of myopathy due to a potential interaction between sodium glucose co-transporter-2 inhibitors (SGLT-2i) and HMG-CoA reductase inhibitors (statins) has been suggested by case reports. OBJECTIVE: We aimed to assess if the reporting of myopathy is disproportionally higher among people using both SGLT-2i and statins compared to using either SGLT-2i or statins alone. METHODS: We conducted a disproportionality analysis using data from the US Food and Drug Administration Adverse Event Reporting System (FAERS). We included reports with at least one antihyperglycemic agent. We compared the proportion of myopathy cases to non-cases between those not using SGLT-2i or statins, using SGLT-2i only, statins only, or both. We calculated the reporting odds ratio and 95% confidence interval. We further stratified by individual SGLT-2i and selected statins (rosuvastatin or atorvastatin). RESULTS: We included 688,388 reports with at least one antihyperglycemic agent recorded, of which 9.80% had at least one SGLT-2i agent. Among all included reports, there were a total of 2202 myopathy cases with the majority, 61.26%, occurring among those using statins alone and only 2.72% of myopathy cases were among those using both SGLT-2i and statins together. Reporting of myopathy was not disproportionally higher among those reporting the use of SGLT-2i with statins (reporting odds ratio 2.95, 95% confidence interval 2.27-3.85) compared to statins alone (reporting odds ratio 6.41, 95% confidence interval 5.86-7.02). CONCLUSIONS: Reports of myopathy were not disproportionally higher among those using SGLT-2i with statins compared to SGLT-2i or statins alone at the class level. Further observational studies may be needed to better assess this interaction at the agent level. |
|---|
| ジャーナル名 | Drug safety |
|---|
| Pubmed追加日 | 2022/3/6 |
|---|
| 投稿者 | Alkabbani, Wajd; Pelletier, Ryan; Beazely, Michael A; Labib, Youssef; Quan, Breanna; Gamble, John-Michael |
|---|
| 組織名 | School of Pharmacy, Faculty of Science, University of Waterloo, 10A Victoria;Street S, Kitchener, ON, N2G 1C5, Canada.;Street S, Kitchener, ON, N2G 1C5, Canada. jm.gamble@uwaterloo.ca. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35247195/ |
|---|
